Headache Trials

Is vaporized cannabis effective for the acute treatment of migraine attacks?

Does a single intravenous infusion of Lu AG09222, an anti-PACAP monoclonal antibody, reduce migraine days in patients with prior preventive treatment failures?

Is vaporized cannabis (THC-dominant, CBD-dominant, or THC+CBD) superior to placebo for the acute treatment of migraine attacks?

Is CGRP inhibitor use associated with an increased risk of cardiovascular events in patients with migraine?

Which treatment strategy—withdrawal, prevention (oral, anti-CGRP, botulinum toxin), education, neurostimulation, or combinations—is most effective at reducing monthly headache days in patients with medication-overuse headache?

Does adding a 28-day prednisone taper to galcanezumab improve outcomes in medication overuse headache compared with either treatment alone?

Is atogepant effective for preventive treatment of chronic migraine in patients with and without acute medication overuse?

Do anti-CGRP monoclonal antibodies effectively prevent attacks in episodic and chronic cluster headache?

Is eptinezumab 400 mg IV every 12 weeks safe, tolerable, and effective for long-term prevention of chronic cluster headache?

Does fremanezumab reduce monthly migraine days and depressive symptoms in patients with migraine and comorbid DSM-5 major depressive disorder?

Is amitriptyline an effective migraine prophylactic, and is the benefit independent of its antidepressant action?

Does eptinezumab combined with brief patient education reduce migraine burden more than patient education alone in adults with chronic migraine and medication-overuse headache?